SCOLR Pharma, Inc. - Introduction to CDT - Controlled Delivery Technology

Technology

Introduction to CDT
State of the Market
CDT Background
     Benefits of CDT
     Platform Summary
     Tech Comparison
     Supporting Literature

	Introduction to SCOLR Pharma CDT®
	Why utilize a controlled release technology?
	Without controlled release technologies people need to take numerous doses of drugs, OTC products and nutritional supplements to realize the benefits. At times this results in undesirable spikes in serum levels, malabsorption and dumping of excessive ingredients and compromised bioavailability. CDT® addresses these concerns by optimizing bioavailability of active ingredients while diminishing adverse side effects, improving dosing compliance and maximizing overall product effectiveness.
	CDT® technologies enable precise control over the timing and amount of active ingredients released. Unique to CDT® technologies are the capability to provide near zero order kinetics over 24 hours; a feature which is difficult, if not impossible, to attain with first generation technologies. How Does CDT® work? SCOLR's platform of patented CDT® technologies enable delivery of active pharmaceutical, OTC, and nutraceutical ingredients from a tablet or capsule over an extended time period. These technologies originated in the mid 1990s during extensive research in the pharmaceutical laboratories of Dr. Reza Fassihi, B. Pharm., Ph.D. at Temple University School of Pharmacy. Since then, this research has led to the development of a wide platform of patented controlled delivery technologies that are the exclusive intellectual property of SCOLR Pharma. The CDT® platform is founded on the art of matrix erosion, changes in gel thickness, electrolyte ionization, and ionic interactions. These are self-correcting systems that lead to carefully controlled erosion as well as a predictable, programmable release of the active ingredient contained in the medicinal core. Previously, this has not been achievable with first-generation delivery systems. This technology enables successful formulation within two different classes of drugs: Class I (high permeability/high solubility) and Class II (high permeability/low solubility). It may also be possible to formulate with certain Class III drugs (low permeability/high solubility), which are historically very problematic.